WO2023065384A1 - 一种人间充质干细胞培养基 - Google Patents

一种人间充质干细胞培养基 Download PDF

Info

Publication number
WO2023065384A1
WO2023065384A1 PCT/CN2021/127005 CN2021127005W WO2023065384A1 WO 2023065384 A1 WO2023065384 A1 WO 2023065384A1 CN 2021127005 W CN2021127005 W CN 2021127005W WO 2023065384 A1 WO2023065384 A1 WO 2023065384A1
Authority
WO
WIPO (PCT)
Prior art keywords
mesenchymal stem
human mesenchymal
acid
culture medium
stem cell
Prior art date
Application number
PCT/CN2021/127005
Other languages
English (en)
French (fr)
Inventor
黄鹏羽
何润邦
刘立会
Original Assignee
中国医学科学院生物医学工程研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国医学科学院生物医学工程研究所 filed Critical 中国医学科学院生物医学工程研究所
Publication of WO2023065384A1 publication Critical patent/WO2023065384A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Definitions

  • the invention relates to a human mesenchymal stem cell culture medium, which belongs to the field of biological materials.
  • MSC Mesenchymal stem cells
  • mesenchymal stem cells are a kind of pluripotent stem cells that have certain differentiation potential and can differentiate into various cell types such as skeletal muscle, cardiac muscle, fat, cartilage, and bone. It can be used clinically for the replacement of target cell groups and the repair of damaged and diseased tissues and organs. It has the function of immune regulation and can play the function of immune reconstruction. Allograft rejection is mild, and the requirements for matching are not strict, so it is widely used.
  • Mesenchymal stem cells mainly exist in bone marrow, and can also be isolated and prepared from fat, synovium, bone, muscle, lung, liver, pancreas and other tissues, as well as amniotic fluid and umbilical cord blood.
  • the purpose of the present invention is to overcome the deficiencies of the prior art and provide a culture medium for human mesenchymal stem cells.
  • a culture medium for human mesenchymal stem cells including fetal bovine serum: 25ml, insulin: 5mg, transferrin: 2.75mg, fibroblast growth factor-2: 5ug, insulin-like growth factor 2: 5ug, taurine: 0.625mg , Putrescine hydrochloride: 0.5mg, Methyl bD-xylopyranoside: 50mg, ⁇ -ketoglutaric acid: 7.3mg, Bovine serum albumin: 0.625g, Linoleic acid: 2.675mg, Cholesterol: 2.5mg, ⁇ -Tocopherol: final concentration 9 ⁇ 10 -7 M, N-acetylcysteine: 5mg, ascorbic acid: 25mg, sodium selenite: 3.35ug, glycine: 3.75mg, L-alanine: 4.45mg, L-Asparagine: 6.6mg, L-Aspartic Acid: 6.65mg, L-
  • the cell culture medium of the present invention can culture human mesenchymal stem cells for more than 30 generations, and the stem cells can still maintain a relatively good shape at the 30th generation, have the ability to proliferate, and can continue to maintain the differentiation properties of human mesenchymal stem cells, that is Possesses the potential to differentiate into fat, cartilage and bone.
  • Figure 1 is the morphology of cultured human mesenchymal stem cells
  • Figure 2 is the proliferation curve of human mesenchymal stem cells
  • Figure 3 is the differentiation ability of human mesenchymal stem cells.
  • DMEM/F12 Dulbecco's modified Eagle medium/nutrient mixture F-12 (manufacturer: Thermo Fisher); other raw materials are commercially available.
  • Embodiment 1 A culture medium for human mesenchymal stem cells, including fetal bovine serum: 25ml, insulin: 5mg, transferrin: 2.75mg, fibroblast growth factor-2: 5ug, insulin-like growth factor 2: 5ug, taurine Acid: 0.625mg, putrescine hydrochloride: 0.5mg, methyl bD-xylopyranoside: 50mg, ⁇ -ketoglutaric acid: 7.3mg, bovine serum albumin: 0.625g, linoleic acid: 2.675mg, cholesterol: 2.5mg, ⁇ -tocopherol: final concentration of 9 ⁇ 10 -7 M, N-acetylcysteine: 5mg, ascorbic acid: 25mg, sodium selenite: 3.35ug, glycine: 3.75mg, L-alanine : 4.45mg, L-Asparagine: 6.6mg, L-Aspartic Acid: 6.65m
  • the umbilical cord was washed thoroughly with saline and cut into small pieces. Cut the umbilical cord longitudinally, and use forceps to peel off two umbilical arteries and one umbilical vein in the umbilical cord. The umbilical cord was cut into small pieces, uniformly inoculated in a T75 culture flask containing 15 mL of a human mesenchymal stem cell culture medium in Example 1, and cultured at 37° C. with 5% carbon dioxide, and the cells obtained were P0 generation cells.
  • the replacement method is to suck up the old medium with a Pasteur pipette and pipette Slowly add an equal amount of new human mesenchymal stem cell culture medium preheated at 37°C to the tube.
  • the specific operation method is:
  • Figure 1 is the morphology of cultured human mesenchymal stem cells, in which:
  • Figure 2 is the proliferation curve of human mesenchymal stem cells.
  • the rhombus point represents the proliferation curve of cells cultured in human mesenchymal stem cell medium (series 1)
  • the circle point represents DMEM+10% FBS (series 2).
  • the human mesenchymal stem cells cultured in the human mesenchymal stem cell medium still proliferate well at the 30th passage, and the human mesenchymal stem cells cultured in DMEM+10% FBS have lost their proliferative ability at the 7th passage.
  • Figure 3 is the differentiation ability of human mesenchymal stem cells.
  • Shown in the figure is a picture of induced differentiation of human mesenchymal stem cells cultured in human mesenchymal stem cell culture medium to the 30th passage or later.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种人间充质干细胞培养基，包括胎牛血清、胰岛素、转铁蛋白、成纤维生长因子-2、胰岛素样生长因子2、牛磺酸、盐酸腐胺、甲基b-D-木吡喃糖苷、α-酮戊二酸、牛血清白蛋白、亚油酸、胆固醇、α-生育酚、N-乙酰半胱氨酸、抗坏血酸、亚硒酸钠、甘氨酸、L-丙氨酸、L-天门冬酰胺、L-天门冬氨酸、L-谷氨酸、L-丝氨酸、L-脯氨酸、丙酮酸钠和DMEM/F12，细胞培养基培养人间充质干细胞，可以传代培养30代以上，到第30代所述干细胞仍然能保持比较好的形态，具有增殖能力，并能继续维持人间充质干细胞的分化属性，即具备向脂肪、软骨和骨的分化潜能。

Description

一种人间充质干细胞培养基 技术领域
本发明涉及一种人间充质干细胞培养基，属于生物材料领域。
背景技术
间充质干细胞(MSC,mesenchymal stem cells)是一种多能干细胞，具有一定的分化潜能，可以分化为骨骼肌、心肌、脂肪、软骨、骨骼等多种细胞类型。应用于临床，可用于目标细胞群的替换和损伤病变组织器官的修复。具有免疫调节功能，可以发挥免疫重建的功能。异体移植排异反应较轻，对配型的要求不严格，因而应用广泛。
间充质干细胞主要存在于骨髓中，也能够从脂肪、滑膜、骨骼、肌肉、肺、肝、胰腺等组织以及羊水、脐带血中分离和制备间充质干细胞。
分离人间充质干细胞后，需要培养人间充质干细胞到足够量，用于分化为目标组织。也需要在培养过程中保持分化潜能。我们发现用传统细胞培养基，以(DMEM+10％FBS)为例，培养人间充质干细胞，细胞到第三代就会出现明显的衰老特征，因此，亟需一种能较多代数培养人间充质干细胞，并且保持其分化潜能的培养基。
发明内容
本发明的目的是克服现有技术的不足，提供一种人间充质干细胞培养基。
本发明的技术方案概述如下：
一种人间充质干细胞培养基，包括胎牛血清：25ml、胰岛素：5mg、转铁蛋白：2.75mg、成纤维生长因子-2：5ug、胰岛素样生长因子2：5ug、牛磺酸：0.625mg、盐酸腐胺：0.5mg、甲基b-D-木吡喃糖苷：50mg、α-酮戊二酸：7.3mg、牛血清白蛋白：0.625g、亚油酸：2.675mg、胆固醇：2.5mg、α-生育酚：终浓度为9×10 -7M、N-乙酰半胱氨酸：5mg、抗坏血酸：25mg、亚硒酸钠：3.35ug、甘氨酸：3.75mg、L-丙氨酸：4.45mg、L-天门冬酰胺：6.6mg、L-天门冬氨酸：6.65mg、L-谷氨酸：7.35mg、L-丝氨酸：5.25mg、L-脯氨酸：5.75mg、丙酮酸钠：27.5mg，用DMEM/F12补齐到500ml。
本发明的优点：
本发明细胞培养基培养人间充质干细胞，可以传代培养30代以上，到第30代所述干细胞仍然能保持比较好的形态，具有增殖能力，并能继续维持人间充质干细胞的分化属性，即具备向脂肪、软骨和骨的分化潜能。
附图说明
图1为培养的人间充质干细胞形态；
图2为人间充质干细胞增殖曲线；
图3为人间充质干细胞分化能力。
具体实施方式
DMEM/F12：杜尔贝科改良Eagle培养基/营养混合物F-12(生产厂家：赛默飞)；其 它原料均为市售。
下面通过具体实施例对本发明作进一步的说明。
实施例1、一种人间充质干细胞培养基，包括胎牛血清：25ml、胰岛素：5mg、转铁蛋白：2.75mg、成纤维生长因子-2：5ug、胰岛素样生长因子2：5ug、牛磺酸：0.625mg、盐酸腐胺：0.5mg、甲基b-D-木吡喃糖苷：50mg、α-酮戊二酸：7.3mg、牛血清白蛋白：0.625g、亚油酸：2.675mg、胆固醇：2.5mg、α-生育酚：终浓度为9×10 -7M、N-乙酰半胱氨酸：5mg、抗坏血酸：25mg、亚硒酸钠：3.35ug、甘氨酸：3.75mg、L-丙氨酸：4.45mg、L-天门冬酰胺：6.6mg、L-天门冬氨酸：6.65mg、L-谷氨酸：7.35mg、L-丝氨酸：5.25mg、L-脯氨酸：5.75mg、丙酮酸钠：27.5mg，用DMEM/F12补齐到500ml。
实施例2
人间充质干细胞的培养：
(1)P0代细胞的获得：
人脐带组织贴壁法分离人间充质干细胞。用生理盐水充分洗涤脐带，并剪成小段。将脐带纵向剪开,用镊子剥去脐带中的两根脐动脉和一根脐静脉。将脐带剪碎，均匀接种于装有15mL实施例1一种人间充质干细胞培养基的T75培养瓶中，37℃，5％二氧化碳培养，得到的细胞即为P0代细胞。
(2)换液
根据步骤(1)的最终的培养基颜色(由原来的红色变成淡黄色)决定更换新的一种人间充质干细胞培养基，更换方法是用巴氏吸管吸掉旧培养基，用移液管，缓慢加入37℃预热的等量新的一种人间充质干细胞培养基。
(3)传代
待细胞密度在85％以上时，分瓶培养即为传代。传代1次即为P1代细胞，以此类推。
具体操作方法为：
a吸掉旧培养基，用37℃预热的pH＝7.4的PBS洗2遍细胞；
b每瓶加TrypLE TM Express胰酶(生产厂家：赛默飞)3ml，室温消化细胞1分钟左右，待细胞变圆后，每瓶加实施例1制备的人间充质干细胞培养基10ml；
c吸出细胞悬液至50ml离心管中，1000rpm，离心3min，弃上清；
d用10ml一种人间充质干细胞培养基重悬沉淀，经细胞筛过滤，5ml人间充质干细胞培养基冲洗筛网，计数；
e调整细胞浓度，根据实际需要铺板或瓶，置于37℃、5％二氧化碳培养箱中培养。
见图1、2和3。
图1为培养的人间充质干细胞形态，其中：
A.DMEM+10％FBS培养人间充质干细胞第3代细胞形态，第3代开始，可以观察到细胞体积增大，出现明显的细胞衰老特征；
B.人间充质干细胞培养基培养人间充质干细胞第1代细胞形态；
C.人间充质干细胞培养基培养人间充质干细胞第3代细胞形态；
D.人间充质干细胞培养基培养人间充质干细胞第30代细胞形态；细胞在第30代依然维持良好的梭形形态，没有明显的细胞衰老特征。
图2为人间充质干细胞增殖曲线。
其中，菱形点表示人间充质干细胞培养基(系列1)培养细胞的增殖曲线，圆形点表示DMEM+10％FBS(系列2)。如图2中所示，人间充质干细胞培养基培养的人间充质干细胞到第30代仍然增殖很好，DMEM+10％FBS培养的人间充质干细胞到第7代已经丢失增殖力。
图3为人间充质干细胞分化能力。
图中所示为人间充质干细胞培养基培养的人间充质干细胞到第30代以后的细胞诱导分化的图片。
A未进行成脂肪诱导，进行油红O染色(脂肪会被染成红色)；
B成脂肪诱导，进行油红O染色(脂肪会被染成红色)；
C未进行成骨诱导，进行茜素红染色(骨会被染成红色)；
D成骨诱导，进行茜素红染色(骨会被染成红色)；
E未进行成软骨诱导，进行阿利新蓝染色(软骨会被染成蓝色)；
F成软骨诱导，进行阿利新蓝染色(软骨会被染成蓝色)。

Claims (1)

  1. 一种人间充质干细胞培养基，其特征是包括胎牛血清：25ml、胰岛素：5mg、转铁蛋白：2.75mg、成纤维生长因子-2：5ug、胰岛素样生长因子2：5ug、牛磺酸：0.625mg、盐酸腐胺：0.5mg、甲基b-D-木吡喃糖苷：50mg、α-酮戊二酸：7.3mg、牛血清白蛋白：0.625g、亚油酸：2.675mg、胆固醇：2.5mg、α-生育酚：终浓度为9×10 -7M、N-乙酰半胱氨酸：5mg、抗坏血酸：25mg、亚硒酸钠：3.35ug、甘氨酸：3.75mg、L-丙氨酸：4.45mg、L-天门冬酰胺：6.6mg、L-天门冬氨酸：6.65mg、L-谷氨酸：7.35mg、L-丝氨酸：5.25mg、L-脯氨酸：5.75mg、丙酮酸钠：27.5mg，用DMEM/F12补齐到500ml。
PCT/CN2021/127005 2021-10-22 2021-10-28 一种人间充质干细胞培养基 WO2023065384A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111233082.0 2021-10-22
CN202111233082.0A CN114958734B (zh) 2021-10-22 2021-10-22 一种人间充质干细胞培养基

Publications (1)

Publication Number Publication Date
WO2023065384A1 true WO2023065384A1 (zh) 2023-04-27

Family

ID=82975204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/127005 WO2023065384A1 (zh) 2021-10-22 2021-10-28 一种人间充质干细胞培养基

Country Status (2)

Country Link
CN (1) CN114958734B (zh)
WO (1) WO2023065384A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170200A1 (en) * 2007-12-31 2009-07-02 Kaohsiung Medical University Stem cell medium
WO2012104936A1 (ja) * 2011-01-31 2012-08-09 独立行政法人医薬基盤研究所 ヒト多能性幹細胞の培養方法
WO2014094386A1 (zh) * 2012-12-20 2014-06-26 上海市第十人民医院 一种干细胞培养基及其应用和干细胞培养方法
CN107043747A (zh) * 2017-06-23 2017-08-15 王晓柯 一种人脐带间充质干细胞无血清培养基
CN109370985A (zh) * 2018-11-12 2019-02-22 王晓柯 一种人脐带间充质干细胞大规模培养无血清培养基

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101735980B (zh) * 2010-02-11 2011-07-27 中国人民解放军总医院 体外培养骨髓间充质干细胞的完全培养基
CN103243070B (zh) * 2013-04-25 2014-07-16 苏州佰通生物科技有限公司 一种干细胞培养基及其应用
CN103805562B (zh) * 2014-01-13 2015-08-05 章毅 培养胎盘间充质干细胞的无血清培养基
CN107475184A (zh) * 2016-06-07 2017-12-15 广州美萨生物科技有限公司 一种用于培养人间充质干细胞的低血清培养基
CN106906182B (zh) * 2017-04-28 2020-10-09 北京赛斯达生物技术有限公司 一种间充质干细胞无血清培养基

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170200A1 (en) * 2007-12-31 2009-07-02 Kaohsiung Medical University Stem cell medium
WO2012104936A1 (ja) * 2011-01-31 2012-08-09 独立行政法人医薬基盤研究所 ヒト多能性幹細胞の培養方法
WO2014094386A1 (zh) * 2012-12-20 2014-06-26 上海市第十人民医院 一种干细胞培养基及其应用和干细胞培养方法
CN107043747A (zh) * 2017-06-23 2017-08-15 王晓柯 一种人脐带间充质干细胞无血清培养基
CN109370985A (zh) * 2018-11-12 2019-02-22 王晓柯 一种人脐带间充质干细胞大规模培养无血清培养基

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOTIROPOULOU P A, ET AL.: "CHARACTERIZATION OF THE OPTIMAL CULTURE CONDITIONS FOR CLINICAL SCALE PRODUCTION OF HUMAN MESENCHYMAL STEM CELLS", STEM CELLS, vol. 24, no. 02, 1 February 2006 (2006-02-01), pages 462 - 471, XP009066391, ISSN: 1066-5099, DOI: 10.1634/stemcells.2004-0331 *
XU, YANG ET AL.: "Comparison of Effect in Two Vitro Culture Systems in Supporting Human Bone Marrow Mesenchymal Stem Cells for Primary Culture, Propagation and Osteogenic Differentiation", FUJIAN MEDICAL JOURNAL, vol. 41, no. 6, 31 December 2019 (2019-12-31), pages 136 - 141, XP009545719 *

Also Published As

Publication number Publication date
CN114958734B (zh) 2023-03-24
CN114958734A (zh) 2022-08-30

Similar Documents

Publication Publication Date Title
CN103060264B (zh) 一种干细胞培养基及其应用和干细胞培养方法
KR101138091B1 (ko) 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제
US9321995B2 (en) Stem cell culture medium and its applications as well as a stem cell culture method
US20150118748A1 (en) High-concentration stem cell production method
KR20130112028A (ko) 무혈청 합성 세포배양 배지
US11339372B2 (en) Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof
US20230117670A1 (en) Bioactive substance composition, serum-free medium comprising the composition, and uses thereof
WO2021254296A1 (zh) 一种生物活性物质组合物、包含所述组合物的无血清培养基及其用途
CN110938590B (zh) 一种间充质干细胞无血清培养基及其用途
CN112048470B (zh) 一种利用人诱导多能干细胞制备临床级别间充质干细胞制剂的方法
CN102899287A (zh) 一种诱导间充质干细胞向软骨细胞分化的方法及其在骨关节炎中的应用
CN106520687B (zh) 一种诱导多能干细胞向间充质干细胞分化的方法
CN105647856A (zh) 促进人脐带间充质干细胞向软骨细胞分化的方法
CN111440764B (zh) 间充质干细胞的无血清培养基及间充质干细胞的临床级规模化培养方法
KR20190060716A (ko) 무혈청 배지 조성물
WO2023065384A1 (zh) 一种人间充质干细胞培养基
Wang et al. Optimizing proliferation and characterization of multipotent stem cells from porcine adipose tissue
JP6721504B2 (ja) 多能性幹細胞及び前駆細胞を生産するためのプロセス
JP2007000077A (ja) 付着性動物細胞の無血清培養方法及び付着性動物細胞の無血清培養用培地
CN111057677B (zh) 一种软骨祖细胞培养基及其制备方法和应用
CN112608892A (zh) 血小板裂解物用于无血清分离和传代培养脐带间充质干细胞的方法
TWI573873B (zh) 體外無血清成體幹細胞放大培養技術
KR102218126B1 (ko) 소변 유래 줄기세포의 미분화능을 유지하는 방법
CN114752560B (zh) 一种脐带间充质干细胞培养基
CN111019889A (zh) 一种间充质干细胞化学成分限定无血清培养基及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21961126

Country of ref document: EP

Kind code of ref document: A1